Grard Marion, Chatelain Camille, Delaunay Tiphaine, Pons-Tostivint Elvire, Bennouna Jaafar, Fonteneau Jean-François
Université de Nantes, Inserm, CRCINA, Nantes, France.
Labex IGO, Immunology Graft Oncology, Nantes, France.
Front Oncol. 2021 Jun 24;11:695770. doi: 10.3389/fonc.2021.695770. eCollection 2021.
Homozygous deletion (HD) of the tumor suppressor gene is the most frequent genetic alteration in malignant pleural mesothelioma and is also frequent in non-small cell lung cancers. This HD is often accompanied by the HD of the type I interferons (IFN I) genes that are located closed to the gene on the p21.3 region of chromosome 9. IFN I genes encode sixteen cytokines (IFN-α, IFN-β…) that are implicated in cellular antiviral and antitumor defense and in the induction of the immune response. In this review, we discuss the potential influence of IFN I genes HD on thoracic cancers therapy and speak in favor of better taking these HD into account in patients monitoring.
肿瘤抑制基因的纯合缺失(HD)是恶性胸膜间皮瘤中最常见的基因改变,在非小细胞肺癌中也很常见。这种HD常伴随着位于9号染色体p21.3区域靠近该基因的I型干扰素(IFN I)基因的HD。IFN I基因编码16种细胞因子(IFN-α、IFN-β等),这些细胞因子参与细胞抗病毒和抗肿瘤防御以及免疫反应的诱导。在本综述中,我们讨论了IFN I基因HD对胸段癌症治疗的潜在影响,并主张在患者监测中更好地考虑这些HD。